TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 1 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,226,051 | +20.3% | 2,150,565 | +106.7% | 0.22% | +19.0% |
| Q2 2023 | $15,978,947 | -50.7% | 1,040,296 | -27.7% | 0.19% | -57.1% |
| Q1 2023 | $32,378,831 | +1488.8% | 1,439,699 | +1385.6% | 0.44% | +1533.3% |
| Q4 2022 | $2,037,975 | -69.2% | 96,908 | -63.9% | 0.03% | -70.7% |
| Q3 2022 | $6,608,000 | +86.7% | 268,175 | +83.8% | 0.09% | +58.6% |
| Q3 2021 | $3,539,000 | – | 145,918 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |